Jennifer Eschbacher

Jennifer Eschbacher

Auto-generated profile, based on publicly available information

Jennifer Eschbacher

Department of Neuropathology, Barrow Neurological Institute , Phoenix, AZ , USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2020 in American Journal of Neuroradiology
Verified
Journal Article
Open access
PDF file
JHJoseph M. Hoxworth
Joseph M. Hoxworth
JEJ.M. Eschbacher
J.M. Eschbacher
AGA.C. Gonzales
A.C. Gonzales
KSK.W. Singleton
K.W. Singleton
GLG.D. Leon
G.D. Leon
LHL.S. Hu
L.S. Hu
BACKGROUND AND PURPOSE: Perfusion MR imaging measures of relative CBV can distinguish recurrent tumor from posttreatment radiation effects in high-grade gliomas. Currently, relative CBV measurement requires normalization based on user-defined reference tissues. A recently proposed method of relative CBV standardization eliminates the need for user input. This study compares the predictive performance of relative CBV standardization against relative CBV normalization for quantifying recurrent tumor burden in high-grade gliomas relative to posttreatment radiation effects. MATERIALS AND METHODS: We recruited 38 previously treated patients with high-grade gliomas (World Health Organization grades III or IV) undergoing surgical re-resection for new contrast-enhancing lesions concerning for recurrent tumor versus posttreatment radiation effects. We recovered 112 image-localized biopsies and quantified the percentage of histologic tumor content versus posttreatment radiation effects for each sample. We measured spatially matched normalized and standardized relative CBV metrics (mean, median) and fractional tumor burden for each biopsy. We compared relative CBV performance to predict tumor content, including the Pearson correlation (r), against histologic tumor content (0%–100%) and the receiver operating characteristic area under the curve for predicting high-versus-low tumor content using binary histologic cutoffs (≥50%; ≥80% tumor). RESULTS: Across relative CBV metrics, fractional tumor burden showed the highest correlations with tumor content (0%–100%) for normalized (r = 0.63, P < .001) and standardized (r = 0.66, P < .001) values. With binary cutoffs (ie, ≥50%; ≥80% tumor), predictive accuracies were similar for both standardized and normalized metrics and across relative CBV metrics. Median relative CBV achieved the highest area under the curve (normalized = 0.87, standardized = 0.86) for predicting ≥50% tumor, while fractional tumor burden achieved the highest area under the curve (normalized = 0.77, standardized = 0.80) for predicting ≥80% tumor. CONCLUSIONS: Standardization of relative CBV achieves similar performance compared with normalized relative CBV and offers an important step toward workflow optimization and consensus methodology.

28 February 2019 in American Journal of Neuroradiology
Verified
Journal Article
Open access
PDF file
LHL.S. Hu
L.S. Hu
HYH. Yoon
H. Yoon
JEJ.M. Eschbacher
J.M. Eschbacher
Leslie C. BaxterLeslie C. Baxter
Leslie C. Baxter
ADAmylou Dueck
Amylou Dueck
JLJing Li
Jing Li
BACKGROUND AND PURPOSE: MR imaging–based modeling of tumor cell density can substantially improve targeted treatment of glioblastoma. Unfortunately, interpatient variability limits the predictive ability of many modeling approaches. We present a transfer learning method that generates individualized patient models, grounded in the wealth of population data, while also detecting and adjusting for interpatient variabilities based on each patient9s own histologic data. MATERIALS AND METHODS: We recruited patients with primary glioblastoma undergoing image-guided biopsies and preoperative imaging, including contrast-enhanced MR imaging, dynamic susceptibility contrast MR imaging, and diffusion tensor imaging. We calculated relative cerebral blood volume from DSC-MR imaging and mean diffusivity and fractional anisotropy from DTI. Following image coregistration, we assessed tumor cell density for each biopsy and identified corresponding localized MR imaging measurements. We then explored a range of univariate and multivariate predictive models of tumor cell density based on MR imaging measurements in a generalized one-model-fits-all approach. We then implemented both univariate and multivariate individualized transfer learning predictive models, which harness the available population-level data but allow individual variability in their predictions. Finally, we compared Pearson correlation coefficients and mean absolute error between the individualized transfer learning and generalized one-model-fits-all models. RESULTS: Tumor cell density significantly correlated with relative CBV (r = 0.33, P < .001), and T1-weighted postcontrast (r = 0.36, P < .001) on univariate analysis after correcting for multiple comparisons. With single-variable modeling (using relative CBV), transfer learning increased predictive performance (r = 0.53, mean absolute error = 15.19%) compared with one-model-fits-all (r = 0.27, mean absolute error = 17.79%). With multivariate modeling, transfer learning further improved performance (r = 0.88, mean absolute error = 5.66%) compared with one-model-fits-all (r = 0.39, mean absolute error = 16.55%). CONCLUSIONS: Transfer learning significantly improves predictive modeling performance for quantifying tumor cell density in glioblastoma.

2 October 2018 in Auditory Perception & Cognition
Verified
Journal Article
Closed access
KPK. Jakob Patten
K. Jakob Patten
MMMichael K. McBeath
Michael K. McBeath
LBLeslie C. Baxter
Leslie C. Baxter
This study examines sound perception and tests the functionality of harmonicity as a metric of auditory preference and regional brain activity. Most salient sounds contain harmonic overtones, a reliable acoustic natural regularity, which we model to computationally define harmonicity. In Experiment 1, listeners rated pairwise similarity of 20 intensity- and f0-matched diverse acoustic stimuli. A multidimensional scaling solution revealed two principal timbre dimensions: tone color and harmonicity. These dimensions, respectively, correlated with the computational measures of spectral-envelope slope (r = 0.51) and RMSE deviation from a harmonic series (r = 0.78). The harmonicity dimension also correlated with rated preference (r = 0.48). This enabled creation of an ordered stimulus-preference continuum that ranged from positive (piano) to negative (hawk screech), used for fMRI tests in Experiment 2. Those results revealed a bilateral primary auditory cortical network for all sounds, but with inharmonic exemplars only producing activation in a fronto-insular cortical network, possibly associated with oddball detection. The results are consistent with dissonant sounds violating the regularity of acoustic-object harmonicity, thereby engaging brain regions associated with unexpected stimuli and attentional focus. The findings confirm harmonicity is an important auditory dimension related to preference, with promise to elicit systematic patterns of cortical network activation.

23 May 2024 in American Journal of Neuroradiology
Verified
Journal Article
Closed access
PDF file
AAAliya Anil
Aliya Anil
Ashley StokesAshley Stokes
Ashley Stokes
JKJohn P. Karis
John P. Karis
LBLaura C. Bell
Laura C. Bell
JEJennifer Eschbacher
Jennifer Eschbacher
Chad QuarlesChad Quarles
Chad Quarles
BACKGROUND AND PURPOSE: DSC-MRI can be used to generate fractional tumor burden (FTB) maps, via application of relative CBV thresholds, to spatially differentiate glioblastoma recurrence from post treatment radiation effects (PTRE). Image-localized histopathology was previously used to validate FTB maps derived from a reference DSC-MRI protocol using preload, a moderate flip angle (MFA, 60°) and post-processing leakage correction. Recently, a DSC-MRI protocol with a low flip angle (LFA, 30°) with no preload was shown to provide leakage-corrected RCBV equivalent to the reference protocol. This study aims to identify the RCBV thresholds for the LFA protocol that generate the most accurate FTB maps, concordant with those obtained from the reference MFA protocol. MATERIALS AND METHODS: Fifty-two patients with grade IV GBM who had prior surgical resection and received chemotherapy and radiotherapy were included in the study. Two sets of DSC-MRI data were collected sequentially first using LFA protocol with no preload, which served as the preload for the subsequent MFA protocol. Standardized relative CBV maps (sRCBV) were obtained for each patient and co-registered with the anatomical post-contrast T1-weighted images. The reference MFA-based FTB maps were computed using previously published sRCBV thresholds (1.0 and 1.56). An ROC analysis was conducted to identify the optimal, voxelwise LFA sRCBV thresholds, and the sensitivity, specificity, and accuracy of the LFA-based FTB maps were computed with respect to the MFA-based reference. RESULTS: The mean sRCBV values of tumors across patients exhibited strong agreement (CCC = 0.99) between the two protocols. Using the ROC analysis, the optimal lower LFA threshold that accurately distinguishes PTRE from tumor recurrence was found to be 1.0 (sensitivity: 87.77%; specificity: 90.22%), equivalent to the ground truth. To identify aggressive tumor regions, the ROC analysis identified an upper LFA threshold of 1.37 (sensitivity: 90.87%; specificity: 91.10%) for the reference MFA threshold of 1.56. CONCLUSION: For LFA-based FTB maps, a sRCBV threshold of 1.0 and 1.37 can differentiate PTRE from recurrent tumor. FTB maps aids in surgical planning, guiding pathological diagnosis and treatment strategies in the recurrent setting. This study further confirms the reliability of single-dose LFA-based DSC-MRI. ABBREVIATIONS: LFA = low flip angle; MFA = moderate flip angle; sRCBV = standardized relative cerebral blood volume; FTB = fractional tumor burden; PTRE = post treatment radiation effects; ROC = receiver operating characteristics; CCC = concordance correlation coefficient.

2 November 2021 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
NSNader Sanai
Nader Sanai
ATAn-Chi Tien
An-Chi Tien
ATArtak Tovmasyan
Artak Tovmasyan
Yu-Wei ChangYu-Wei Chang
Yu-Wei Chang
TMTigran Margaryan
Tigran Margaryan
ZMZaman Mirzadeh
Zaman Mirzadeh
5-Aminoleveulinic acid sonodynamic therapy (5-ALA SDT) is a drug-device strategy that exploits the metabolic liabilities of cancer. Following systemic administration of 5-ALA, aberrant tumor metabolism leads to accumulation of protoporphyrin-IX (PpIX). Activation of PpIX by non-invasive, non-ablative magnetic resonance-guided focused ultrasound (MRgFUS) induces reactive oxygen species and tumor cell death. This first-in-human Phase 0/1 study investigates the feasibility, safety, and biological effects of 5-ALA SDT in recurrent glioblastoma (GBM) patients. Six hours prior to SDT, adult patients with recurrent GBM are administered Sonala-001 (10mg/kg), an IV formulation of 5-ALA. In a Dose-Escalation Arm, 9-18 patients are assigned to one of three ascending acoustic energy doses of MRgFUS (200J/400J/800J, measured at transducer surface), followed by a four-day interval to planned tumor resection. In each patient, half the tumor volume, including Gadolinium-enhancing and nonenhancing tumor, is targeted with MRgFUS and the other half serves as an internal control. Using tumor pharmacodynamic endpoints, the Minimum Biological Dose (MBD) associated with 5-ALA SDT response is identified. In a subsequent Time-Escalation Arm, 12 patients are treated at the MBD and assigned to one of two time-intervals between SDT and resection. As of May 1, accrual to the 200J dose level (n=3) is complete without significant drug- or device-related adverse events. No cellular or radiographic changes to non-targeted tissue were detected. The median Cmax for 5-ALA and PpIX were 307 µM and 319 nM, respectively. The oxidative stress biomarkers 4-hydroxynonenal, glutathione, cysteine, and thiol were significantly elevated in treated tissue vs. control. Similarly, the apoptosis biomarker cleaved caspase-3 was increased in treated tumor vs. control (median, 48.6% vs. 29.6%, p=0.05). This first-in-human experience with a new therapeutic modality for recurrent glioblastoma patients demonstrates that 5-ALA SDT is safe at 200J. Sonodynamic therapy leads to targeted oxidative stress and tumor cell death in human glioblastoma tissue.

6 April 2015 in Neurology
Verified
Journal Article
Closed access
GZGlynnis Zieman
Glynnis Zieman
CDChristopher Dardis
Christopher Dardis
AGAndrea Gomes
Andrea Gomes
Adrienne C ScheckAdrienne C Scheck
Adrienne C Scheck
JEJennifer Eschbacher
Jennifer Eschbacher
LALynn Ashby
Lynn Ashby